expression from a nucleic acid introduced into said patient u201d this means that a nucleic acid such as a dna is introduced into a cell of said patient for example a skin cell for example by means of a viral vector carrying said sequence by protein expression from said nucleic acid a protein with the amino acid sequence encoded by said nucleic acid is generated inside said patient the term u201c administered externally u201d as used herein in the context of a protein being administered externally refers to a way of delivering a protein in which the protein is not delivered by generating it inside said patient by protein expression but in which the protein is delivered from the outside optionally in the form of a precursor protein the term u201c pharmaceutically acceptable carrier u201d refers to a non toxic inert solid semi solid or liquid diluent material or formulation auxiliary of any type u201c pharmaceutically acceptable u201d in this context is meant to designate that said carrier is compatible with the other ingredients of the pharmaceutical composition and not harmful to the patient that the pharmaceutical composition is administered to examples of pharmaceutically acceptable carriers include but are not limited to water water propylene glycol solutions or aqueous polyethylene glycol solutions fig1 shows decreased s100a7 expression and production in keloid tissue panel a shows the result of real time qpcr real time quantitative polymerase chain reaction for s100a7 expression carried out from rna of normal skin ns and keloid scar tissue prepared according to example 1 panel b shows western blot analysis of whole cell lysates probed with specific antibodies against s100a7 and u03b2 actin loading control according.